Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Cardiac Event Clear all
Completed No phase listed Observational

Impact of OSA on Outcomes in Acute Coronary Syndrome

NCT03793582
View directory record Official record
Conditions
OSA, ACS - Acute Coronary Syndrome, Major Adverse Cardiac Events
Interventions
ApneaLink Type III portable sleep study
Diagnostic Test
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 21, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional Results available

Phase III Acute Coronary Syndrome

NCT00831441
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
7,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 21, 2026, 6:35 PM EDT
Recruiting Phase 4 Interventional

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

NCT06802224
View directory record Official record
Conditions
Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions
Norepinephrine, Phenylephrine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

NCT02924727
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 21, 2026, 6:35 PM EDT
Completed No phase listed Observational

Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)

NCT02332070
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency
Interventions
cardiac surgery
Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
Not listed
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

NCT04363697
View directory record Official record
Conditions
Acute Heart Failure, Heart Failure
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
2,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

NCT02145468
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 21, 2026, 6:35 PM EDT
Active, not recruiting Phase 4 Interventional

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

NCT05284747
View directory record Official record
Conditions
Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
Interventions
Evolocumab, Routine Lipid Management
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
6,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
81
States / cities
Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Study Effect of VIA-2291 on Vascular Inflammation

NCT00358826
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
VIA-2291, Placebo
Drug
Lead sponsor
Tallikut Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Melbourne, Florida • Minneapolis, Minnesota • Tupelo, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Serious Adverse Events Following Angiography

NCT01467466
View directory record Official record
Conditions
Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions
IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 21, 2026, 6:35 PM EDT
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 21, 2026, 6:35 PM EDT
Not yet recruiting Not applicable Interventional

WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

NCT07558265
View directory record Official record
Conditions
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 21, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897
View directory record Official record
Conditions
Cardiac Surgery
Interventions
teprasiran, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Not applicable Interventional Results available

Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events

NCT06048068
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Educational Informational Platform
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

NCT01042769
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Aleglitazar, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
7,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
221
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 181 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 21, 2026, 6:35 PM EDT
Terminated Not applicable Interventional

Positive Emotions After Acute Coronary Events at Northwestern University

NCT04062383
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
Positive Psychology + Motivational Interviewing
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

NCT02415400
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 95 Years
Enrollment
4,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
143
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

NCT00335452
View directory record Official record
Conditions
Acute Coronary Disease, Angina Unstable
Interventions
Clopidogrel, acetylsalicyclic acid (ASA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
25,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 21, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

The Dual Antiplatelet Therapy Study (DAPT Study)

NCT00977938
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo & Aspirin, Clopidogrel & Aspirin, Prasugrel & Aspirin
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
25,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
178
States / cities
Fairhope, Alabama • Gilbert, Arizona • Phoenix, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 21, 2026, 6:35 PM EDT
Recruiting Phase 3 Interventional

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928
View directory record Official record
Conditions
Myocarditis Acute, Cancer
Interventions
Abatacept plus, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
29
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 21, 2026, 6:35 PM EDT